<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="147805">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01176266</url>
  </required_header>
  <id_info>
    <org_study_id>ENB-010-10</org_study_id>
    <nct_id>NCT01176266</nct_id>
  </id_info>
  <brief_title>Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)</brief_title>
  <official_title>An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of Asfotase Alfa (Human Recombinant Tissue-nonspecific Alkaline Phosphatase Fusion Protein) in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharma GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is being conducted to study hypophosphatasia (HPP), a bone disorder
      caused by gene mutations or changes. These gene mutations cause low levels of an enzyme
      needed to harden bone. The purpose of this study is to test the safety and efficacy of a
      study drug called asfotase alfa (human recombinant tissue non-specific alkaline phosphate
      fusion protein) to see what effects it has on patients ≤ 5 years of age or less with HPP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Asfotase alfa was formerly referred to as ENB-0040

      Hypophosphatasia (HPP) is a life-threatening, genetic, and ultra-rare metabolic disease
      characterized by defective bone mineralization and impaired phosphate and calcium regulation
      that can lead to progressive damage to multiple vital organs, including destruction and
      deformity of bones, profound muscle weakness, seizures, impaired renal function, and
      respiratory failure. There are no approved disease-modifying treatments for patients with
      this disease. There is also limited data available on the natural course of this disease
      over time, particularly in patients with the juvenile-onset form.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of asfotase alfa treatment on skeletal manifestations of HPP</measure>
    <time_frame>Up to 72 months or until regulatory approval</time_frame>
    <description>Effect of asfotase alfa treatment on skeletal manifestations of HPP as measured by radiographs using a qualitative Radiographic Global Impression of Change (RGI-C) scale for all treated patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of repeated subcutaneous (SC) injections of asfotase alfa</measure>
    <time_frame>Up to 72 months or until regulatory approval</time_frame>
    <description>Safety and tolerability of repeated subcutaneous (SC) injections of asfotase alfa for all treated patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of asfotase alfa treatment on ventilator-free survival</measure>
    <time_frame>Up to 72 months or until regulatory approval</time_frame>
    <description>For patients who are not mechanically ventilated at the time of enrollment, the percentage who are alive and ventilator-free after receiving asfotase alfa as compared to an age-matched historical control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of asfotase alfa treatment on respiratory function</measure>
    <time_frame>Up to 72 months or until regulatory approval</time_frame>
    <description>Effect of asfotase alfa treatment on respiratory function as measured by ventilator status, time on respiratory support (including time on ventilator or supplemental oxygen), ventilator rate or oxygen volume, ventilator pressures, and fraction of inspired oxygen (FiO2) for all treated patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of asfotase alfa treatment on physical growth</measure>
    <time_frame>Up to 72 months or until regulatory approval</time_frame>
    <description>Effect of asfotase alfa treatment on physical growth as measured by body weight, length, arm span, head circumference, and chest circumference for all treated patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of asfotase alfa treatment on tooth loss</measure>
    <time_frame>Up to 72 months or until regulatory approval</time_frame>
    <description>Effect of asfotase alfa treatment on tooth loss for all treated patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) properties of asfotase alfa</measure>
    <time_frame>Up to 72 months or until regulatory approval</time_frame>
    <description>The PK properties of asfotase alfa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of asfotase alfa on biomarkers</measure>
    <time_frame>Up to 72 months or until regulatory approval</time_frame>
    <description>Effect of asfotase alfa on plasma inorganic pyrophosphate (PPi) and plasma pyridoxal-5' phosphate (PLP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of asfotase alfa on serum parathyroid hormone (PTH)</measure>
    <time_frame>Up to 72 months or until regulatory approval</time_frame>
    <description>Effect of asfotase alfa on serum parathyroid hormone (PTH)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Hypophosphatasia</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>asfotase alfa</intervention_name>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients must meet all of the following criteria for enrollment in this study:

          -  Parent or legal guardian(s) must provide written informed consent prior to any study
             procedures being performed and must be willing to comply with all study-required
             procedures

          -  Documented diagnosis of HPP as indicated by:

               -  Total serum alkaline phosphatase below the lower limit of normal for age

               -  Plasma PLP above the upper limit of normal (unless patient is receiving
                  pyridoxine for seizures)

               -  Radiographic evidence of HPP, characterized by:

                    -  Flared and frayed metaphyses

                    -  Severe, generalized osteopenia

                    -  Widened growth plates

                    -  Areas of radiolucency or sclerosis

               -  Two or more of the following HPP-related findings:

                    -  History or presence of:

                         -  Nontraumatic post-natal fracture

                         -  Delayed fracture healing

                    -  Nephrocalcinosis or history of elevated serum calcium

                    -  Functional craniosynostosis

                    -  Respiratory compromise or rachitic chest deformity

                    -  Vitamin B6 dependent seizures

                    -  Failure to thrive

          -  Onset of symptoms prior to 6 months of age

          -  Chronological age or adjusted age for premature infants born ≤ 37 weeks gestation of
             ≤ 5 years

          -  Otherwise medically stable in the opinion of the Investigator and/or Sponsor

          -  Patients with low 25(OH) vitamin D levels are eligible for study participation after
             correction of levels with vitamin D supplementation.

        Exclusion criteria:

        Patients will be excluded from enrollment in this study if they meet any of the following
        exclusion criteria:

          -  Clinically significant disease that precludes study participation, in the opinion of
             the Investigator and/or Sponsor

          -  Serum calcium or phosphate levels below the normal range

          -  Current evidence of treatable form of rickets

          -  Prior treatment with bisphosphonates

          -  Treatment with an investigational drug within 1 month prior to the start of asfotase
             alfa treatment

          -  Current enrollment in any other study involving an investigational new drug, device
             or treatment for HPP (e.g., bone marrow transplantation)

          -  Intolerance to the IP or any of its excipients

          -  Previous participation in the same study

          -  Family relative of the Investigator

        NOTE: Historical values for PLP may be used to determine patient eligibility.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Children's Hospital &amp; Research Center Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lady Cilento Children's Hospital</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Children'S Hospital</name>
      <address>
        <city>Parkville Victoria</city>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Sciences Centre Winnipeg, University of Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1S1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Necker Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätskinderklinik Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>D-97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Giannina Gaslini</name>
      <address>
        <city>Genova</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gesù</name>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuoka Higashi Medical Hospital</name>
      <address>
        <city>Koga-city</city>
        <state>Fukuoka</state>
        <zip>811-3195</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ishikawa Prefectural Hospital</name>
      <address>
        <city>Kanazawa-city</city>
        <state>Ishikawa</state>
        <zip>920-8530</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Municipal Hospital</name>
      <address>
        <city>Saitama-city</city>
        <state>Saitama</state>
        <zip>336-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University Hospital</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Marianna University School of Medicine, Yokohayama City Seibu Hospital</name>
      <address>
        <city>Yokohama-city, Kanagawa</city>
        <state>Yokohama-city</state>
        <zip>241-0811</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Institution</name>
      <address>
        <city>Moscow</city>
        <zip>117036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Faisal Specialist Hospital and Research Center</name>
      <address>
        <city>Riyadh</city>
        <state>KSA</state>
        <zip>11211</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil Universitario Nino Jesus</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uludag Universitesi Hastanesi</name>
      <address>
        <city>Nilüfer</city>
        <state>Bursa</state>
        <zip>16059</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Children's Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B4 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Children'S Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheffield Children'S Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Russian Federation</country>
    <country>Saudi Arabia</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Taiwan</country>
  </removed_countries>
  <link>
    <url>http://www.hypophosphatasie.com</url>
    <description>Hypophosphatasie Europe</description>
  </link>
  <link>
    <url>http://www.magicfoundation.org</url>
    <description>HPP support group</description>
  </link>
  <link>
    <url>http://health.groups.yahoo.com/group/Hyphosphatasia</url>
    <description>Yahoo health group for HPP with an international list serve where patients can correspond and post questions to the group</description>
  </link>
  <link>
    <url>http://www.softbones.org</url>
    <description>US Hypophosphatasia Group (Soft Bones)</description>
  </link>
  <link>
    <url>http://www.hypophosphatasia.com</url>
    <description>Hypophosphatasia Website</description>
  </link>
  <link>
    <url>http://www.hypophosphatasia.com/hcp/</url>
    <description>Hypophosphatasia Website for Healthcare Providers</description>
  </link>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 14, 2016</lastchanged_date>
  <firstreceived_date>July 29, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypophosphatasia</keyword>
  <keyword>HPP</keyword>
  <keyword>Bone Disease</keyword>
  <keyword>Soft Bones</keyword>
  <keyword>Low Alkaline Phosphatase</keyword>
  <keyword>genetic metabolic disorder</keyword>
  <keyword>alkaline phosphatase</keyword>
  <keyword>tissue-specific alkaline phosphatase (TNSALP)</keyword>
  <keyword>rickets</keyword>
  <keyword>osteomalacia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypophosphatasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
